• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Guaranteed Paid Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Prostate Cancer Surgery Myths and ... Lies, Lies and More Damned Lies


News provided by

Dr. Bert Vorstman

Jan 31, 2012, 07:30 ET

Share this article

Share this article


CORAL SPRINGS, Fla., Jan. 31, 2012 /PRNewswire/ -- Dr. Bert Vorstman, a urologist with nearly 30 years expertise in prostate cancer diagnosis and treatment, is challenging the validity of curative life extension claims promoted by manufacturers and surgeons employing radical prostate surgery/robotics.

(Logo: http://photos.prnewswire.com/prnh/20120131/CL41145 )

Continue Reading

Dr. Vorstman addresses these inconsistencies in an extensive treatise on prostate surgery at http://www.urologyweb.com/urology/mens-health/prostate-cancer/prostate-cancer-surgery.html and responds to common myths and mis-statements involving diagnosis and "junk science" applied to promoting this surgical treatment.

Top 10 Prostate Cancer Myths, Misconceptions and Outright Lies

1.  I've been diagnosed with prostate cancer and I've got to act quickly before it spreads.

Dr. Vorstman:  The first order of business is to take a deep breath, relax and then review and evaluate all treatment options.  Cancer is an emotionally charged word causing anxiety and an inappropriate rush to judgment. Due to a generally slow growth and indolent nature, MOST prostate cancers are unlikely to impact most men during their lifetime. Though the second leading cause of cancer related deaths for men, only some 7% of men will actually die from prostate cancer.  Clearly, prostate cancer is not going to "spread" while a man enters a period of active surveillance (AS) seeking out second opinions and empowering and educating himself on treatment options.  In particular, many small volume low risk cancers can often be followed for several years.

2.  My PSA (Prostatic Specific Antigen) test is abnormal and my doctor has suggested evaluation.

Dr. Vorstman: Never take any action based upon just one abnormal PSA.

Fundamentally, the PSA is a flawed screening test for prostate cancer as it screens more for benign prostatic disease and is not an accurate validation for early prostate cancer detection. Its value is in post prostate cancer treatment monitoring. Furthermore, if you have significant co-morbidities such as heart disease or diabetes, or have a life expectancy of 10 years or less, PSA evaluation is unlikely to be of any benefit to you as you are very likely to outlive any existing prostate cancer.

3.  A digital rectal examination shows indication of an irregularity, lump or nodule. A blood screening shows a normal PSA. Should I agree to a biopsy as a next step?

Dr. Vorstman:  A digital exam's accuracy, much like a typical PSA blood test, is like tossing a coin—a 50 percent chance.  Men should understand that:

  1. You can have a prostate nodule that is cancerous but your PSA is "normal",
  2. 15-20% of men with a normal PSA under 4ng/ml can have prostate cancer, and
  3. Some 30% of men with a PSA between 4-10ng/ml will have significant prostate cancer.  Although a needle biopsy of the prostate might carry its own complications for the patient, it is the only way to determine if cancer exists.

4.  My doctor wants to discuss my biopsy results and next steps.

Dr. Vorstman: Firstly, you need to send your biopsy slides out to a nationally recognized reference laboratory so your diagnosis, benign or malignant, can be validated.  Unfortunately, there is a huge discordance rate amongst pathologists on reading the same slides and patients should only consider further actions on their diagnosis based on a consensus of reliable pathology results. Secondly, you should know exactly where your cancer was found in your prostate as significant cancer at the base or apex can mean that the cancer is no longer confined to the prostate and that only radiation would be a reasonable treatment option. Thirdly, you should realize that CAT scan and bone scan studies are of no value in determining the status of your cancer if your PSA is less than 15ng/ml.  

5.  Prostate cancer surgery/robotics, an often recommended and "cutting" edge treatment, is offered by many urologists with curative intent.

Dr. Vorstman: Although offered with curative intent, it is known that there is NO scientific validation for significant curative life extension after radical surgery/robotics for prostate cancer. In fact, this one surgery is associated more with permanent complications (especially incontinence and impotence) than probably any other operation ever performed on humans.  Unfortunately, this radical surgery is often treated as an emergency, but is a heavy-handed approach without merit and probably without equal, in providing false hope. Surgery has also been shown to have a high rate of inadequate cancer control (residual cancer) in some 20-40% of patients. These negative quality of life issues should be considered before submitting to an invasive and irreversible surgical procedure.

6.  My friend, who underwent radical surgery, says he is fine and he has no complications.

Dr. Vorstman: I'm sure that there are some men who claim no complications following radical surgery/robotics for their prostate cancer. However, in addition to shortening of the penis and a high rate of residual cancer in men after radical surgery/robotics, many men are often too embarrassed to admit to post operative urinary leakage and issues of a sexual nature. These quality of life issues clearly underscore the fact that surgery/robotics is no panacea for prostate cancer treatment. Surgeons as well as marketers continue to promote robotic technology for radical prostatectomy by a creative spin, using such terms as "advanced",  "minimally invasive", and "superior outcomes."  The sad truth is that prostate cancer surgery is solely responsible for the worldwide increase in urinary incontinence and impotence but without the benefit of curative life extension.

7.  But they say surgery is the "Gold Standard" in prostate cancer treatment and it is FDA approved.

Dr. Vorstman: The term "Gold Standard" is a very unfortunate, self-anointed, self-serving term, which implies established and proven benefits for radical surgery/robotics in the treatment of prostate cancer when the truth is far from it.  Surgery is simply the oldest treatment modality for prostate cancer, and because of this history, is deemed as the "Gold Standard".

Yes, robotic surgery for prostate cancer is FDA approved but the technology was simply given a "pass" by the agency without the benefit of rigorous scientific evaluation for risk or reward.  There is no other high-risk surgical technology for prostate cancer to be so approved.

8.  I'm conflicted about treatment options as most prostate cancer is currently treated by either surgery/robotics or radiation. What about Cyroablation or HIFU?

Dr. Vorstman:  First let me say that it is absolutely the patient's prerogative as to what treatment modality he chooses, if at all, to treat his prostate cancer.  After any diagnosis—especially when cancer is suspected—it is imperative for the patient to empower himself and seek out several opinions. Most of the information given by physicians will be skewed with bias, but often, a patient can work around this issue by researching and seeking second and third opinions. Most men are offered either surgery or one of the several radiation options as most urologists have no experience in the minimally invasive options of Cryoablation (Outpatient percutaneous placement of cyroprobes into prostate for freeze-thaw cycles to iceball prostate) or HIFU (high intensity focused ultrasound of the prostate gland). Since all of the treatment options have similar survival benefits, it is important for men and their partners to be sure that they understand the various complications that may be associated with the different treatment modalities.

9.  Prostate cancer is prostate cancer—all are the same.

Dr. Vorstman:  NOT true and patients need to be wary of following the treatment experienced by a friend, who may have a different Gleason grade, tumor location and tumor volume. Because of these differences, not all treatment modalities may be suitable for every prostate cancer.  And, as a general overview, it should be clearly understood that most men will die with and not from prostate cancer, so the disease if far from a "death sentence."

10.  My urologist tells me that I've been "successfully treated" through radical robotic surgery. Does that mean I'm cancer free and can I expect my leakage and erections to improve to the same quality of life I had before the surgery?

Dr. Vorstman: Every man expects curative life extension after treatment of his prostate cancer, no complications and with a full return of normal daily activities and the quality of life he had before surgery.  This happens rarely, if ever, after radical surgery/robotics for localized prostate cancer.  It's a naive dream propagated through marketers and pursued by many surgeons.  Furthermore, because the prostate cancer cell is generally quite slow growing, survivorships of 10-15 years after surgery are meaningless as metastases may present 20-30 years after surgery.

About Bert Vorstman MD, MS, FAAP, FRACS, FACS

Dr. Vorstman is a urological surgeon with 30 years of experience. He is Fellowship trained in Pediatric and Adult reconstructive Urology, a former NIH surgeon researcher and a former Urology Faculty Member at the University of Miami, Florida. He also earned the honor of a Masters of Surgery Diploma through Otago University, Dunedin, New Zealand for pioneering research on urinary bladder reinnervation using nerve cross over techniques. These techniques could have possible application in patients with neurogenic bladders.

Dr. Vorstman's passion and dedication is to help men and their partners fully understand the treatment options available to them as well as their possible complications when facing a diagnosis of prostate cancer.

He works to promote the acceptance and use of minimally invasive treatment options such as HIFU and Cryoablation for localized prostate cancer in appropriately selected men. In that regard, he has developed a Center for Minimally Invasive Treatment Options for localized prostate cancer.

In addition, Dr. Vorstman has developed a leading urology practice, Florida Urological Associates, PA, was instrumental in developing the Coral Springs Surgical Center and developed websites highlighting prostate cancer issues including www.urologyweb.com

SOURCE Dr. Bert Vorstman

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.